Close Menu

NEW YORK (GenomeWeb) – Illumina and China firm Boai NKY Medical Holdings have partnered to develop next-generation sequencing-based hereditary disease tests in China.

Under the agreement announced on Tuesday, NKY and Illumina will develop an NGS system based on Illumina's MiniSeq system and NKY's library prep kits and analysis software to develop in vitro diagnostics for hereditary kidney disease. The goal is to develop a platform that will meet regulatory criteria of China's National Medical Products Administration.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.

Jun
04
Sponsored by
NanoCellect

This webinar will discuss a study that used CRISPR/Cas9 to engineer mice harboring risk variants associated with glaucoma in order to assess their functional relevance. 

Jun
06
Sponsored by
NRGene & Illumina

This webinar will discuss the impact of affordable de novo genome assemblies on crop research.

Jun
11
Sponsored by
Roche

This webinar will overview the potential for liquid biopsy approaches to monitor therapy resistance in lung cancer.

Jun
13
Sponsored by
Roche

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type.